Genetic Testing Fraud Defense
Former DOJ Healthcare Fraud Unit Prosecutors. Nationwide Defense for Laboratory Owners, Physicians, Marketers, Call Center Operators, Telemedicine Executives, and Investors in Federal Genetic Testing Fraud Investigations and Trials.
Based in Washington, D.C., Armstrong & Bradylyons PLLC defends laboratory owners, physicians, nurse practitioners, marketers, telemedicine operators, call center owners, patient recruiters, and executives in federal genetic testing fraud investigations and prosecutions nationwide.
The firm’s healthcare fraud defense practice is built on nearly a decade of combined service at the nation’s leading healthcare fraud enforcement unit: the Healthcare Fraud Unit of DOJ’s Fraud Section, now housed in the Department’s National Fraud Enforcement Division. Scott Armstrong, Drew Bradylyons, and Andrea Savdie tried 17 federal jury trials in healthcare fraud cases at DOJ involving over $2.8 billion in alleged false and fraudulent claims to federal healthcare programs. The firm uses that experience at every stage of a genetic testing case: the first payment suspension, the grand jury subpoena, the indictment, and the trial.
Genetic testing remains one of the highest-priority targets of federal healthcare fraud enforcement. The June 2026 National Health Care Fraud Takedown charged laboratory and call center operators in genetic testing schemes, and the FBI added two fugitive genetic testing defendants to its Most Wanted Fraudsters List the same day. CMS is suspending and revoking laboratory billing privileges on a scale it has never attempted before. The firm defends individuals in every federal district where these cases are brought.
The government tries these cases. DOJ’s Healthcare Fraud Unit completed nine jury trials in the first half of 2026, securing convictions in all of them, after 17 trials in 2025. A defense built on the assumption that a genetic testing case will resolve short of trial is a defense built on a bad assumption. Armstrong & Bradylyons PLLC prepares every case for a jury from the day it opens.
Trial preparation produces leverage at every earlier stage. Genetic testing prosecutions are built on claims data, referral chain analysis, sham marketing contracts, and cooperating witnesses. They involve CGx and PGx test orders, physician certifications, per-sample and percentage-based marketer payments, and allegations that tests were medically unnecessary or that orders came from providers who never treated the patient. The firm builds the factual record immediately: analyzing billing data, retaining clinical and statistical experts, identifying and preparing witnesses, and developing a theory of defense that survives cross-examination.
The firm’s attorneys know how these prosecutions are built because they built them. Scott Armstrong served nearly a decade at DOJ’s Fraud Section as Director of the Appalachian Regional Prescription Opioid Strike Force, as an Assistant Chief in the Market Integrity and Major Frauds Unit, and as a leading trial attorney in the Healthcare Fraud Unit. He tried 16 federal jury trials, nine of them healthcare fraud trials, and served as lead counsel in cases involving more than $600 million in claims to federal programs. Drew Bradylyons served as an Assistant Chief in the Healthcare Fraud Unit, where he supervised the Miami Strike Force, and as Chief of the Financial Crimes and Public Corruption Unit at the U.S. Attorney’s Office for the Eastern District of Virginia, where he supervised parallel civil, criminal, and administrative proceedings involving more than $1 billion in claims to Medicare, Medicaid, and TRICARE.
That background matters in a laboratory case for a specific reason. The government’s theory in a genetic testing prosecution is assembled from claims data, bank records, marketing agreements, and cooperator narratives long before anyone is charged. Counsel who have assembled those cases can see the gaps in them.
Genetic testing fraud has been a top-tier DOJ priority since September 2019, when the Department launched Operation Double Helix and charged 35 defendants in schemes that billed Medicare more than $2.1 billion for CGx and PGx testing. The 2026 record shows that priority intensifying. The Department reorganized, the payment system began blocking money before claims are paid, and juries kept convicting.
The 2026 National Health Care Fraud Takedown
On April 7, 2026, DOJ established the National Fraud Enforcement Division and moved the Healthcare Fraud Unit under it. Nine healthcare fraud strike forces now operate nationwide, supported by a data science team and a National Fraud Detection Center.
On June 23, 2026, the new Division announced the 2026 National Health Care Fraud Takedown: 455 defendants charged across 56 federal districts, including 90 licensed medical professionals, in schemes involving more than $6.5 billion in alleged false claims. Agents seized over $182 million in assets. CMS suspended 1,079 providers and revoked billing privileges for 1,403 more.
Two genetic testing matters featured in the announcement. A South Florida call center owner was charged in a $62 million scheme alleging that he sold doctors’ orders for genetic tests to laboratories, used deceptive telemarketing to secure beneficiary agreement, and then “doctor chased” treating physicians with faxes containing false representations designed to induce them to sign. The same day, the FBI added two genetic testing fugitives to its Most Wanted Fraudsters List: one wanted in a $547 million scheme who fled after release on bond over the government’s objection, and a laboratory owner wanted in a $90 million scheme who removed her ankle monitor and left the country.
Convictions and Sentences in 2026
In February 2026, a federal jury in Dallas convicted a Texas laboratory owner in a $328 million cardiovascular genetic testing case built on per-sample kickbacks to marketers concealed through invoices for marketing hours, software, and loans that did not exist. In May 2026, the operator of four laboratories was sentenced to 151 months in a $522 million scheme, with restitution over $84.5 million. Eleven co-conspirators had already pleaded guilty and been sentenced, including three physicians, two nurse practitioners, and six marketers, receiving terms ranging from probation to 46 months. The government charges the entire chain, and outcomes vary widely by role, conduct, and preparation.
CMS and HHS-OIG on the Payment Side
The most significant change for laboratories is that money now stops before claims are paid. CMS announced in August 2026 that it had stopped more than $1.6 billion in potentially improper laboratory payments, including $732 million from revoking 157 laboratory providers and more than $500 million halted through 185 payment suspensions arising from an investigation of 600 laboratories. The agency credits machine learning models applied to fee-for-service claims. Its genetic testing fact sheet reports more than $73.2 million in targeted denials in 2026 and identifies billing for tests ordered by providers with no established relationship to the beneficiary as a priority target.
HHS-OIG opened a parallel review. Its June 2026 Work Plan project, Trends and Vulnerabilities in Genetic Tests Covered Under Medicare Part B, notes that Part B spending on genetic tests exceeded $3.6 billion in 2024 and will examine geographic variation between jurisdictions that do and do not participate in the Molecular Diagnostic Services Program. Reviews of this kind generate audits, referrals, and the statistical foundation for later criminal cases.
A genetic testing case usually runs on more than one track at once. A criminal investigation may proceed alongside a payment suspension, a revocation action, an OIG audit, and a sealed qui tam complaint. Each track creates evidence the others can use. The firm manages all of them together.
Challenging the Government’s Billing and Utilization Analysis
Federal genetic testing cases begin with data. CMS, the Healthcare Fraud Unit’s Data Analytics Team, and the interagency Data Fusion Center use predictive models to flag laboratories whose volume, test mix, or reimbursement patterns deviate from statistical norms. The firm retains forensic billing analysts to test the government’s methodology, peer group selection, outlier designations, extrapolation, and summary exhibits. Billing volume is not proof of fraud. Comparator sets can be wrong. Summary charts prepared by agents are subject to challenge under Rule 1006 and can be dismantled on cross-examination.
Establishing Medical Necessity for CGx and PGx Testing
The government’s case often turns on the assertion that testing was medically unnecessary. Medicare covers CGx testing in narrow circumstances tied to a personal or family history of cancer and use of the results in an active treatment plan. PGx coverage is limited to specific drug-gene interactions. Coverage also varies by Medicare Administrative Contractor jurisdiction, which OIG has itself identified as a source of inconsistency. The firm retains independent genetics experts and oncologists to evaluate testing against clinical standards and applicable coverage determinations, and to confront the government’s experts at trial.
Analyzing Marketer Compensation Under the AKS and EKRA
Prosecutors treat per-sample and percentage-based marketer payments as the core kickback theory in laboratory cases under the Anti-Kickback Statute, and increasingly under EKRA, which reaches laboratory referrals regardless of payer. The firm analyzes compensation structures against safe harbor regulations and OIG advisory opinions, examines fair market value support, and distinguishes documented marketing services from payments reverse-engineered to match referral volume. Failure to satisfy a safe harbor does not establish a violation. The government still must prove knowing and willful conduct.
Challenging Proof of Knowledge and Willfulness
Healthcare fraud and Anti-Kickback Statute convictions require proof of knowing and willful conduct. The firm develops evidence of compliance programs, legal review of marketing agreements, documented clinical rationale, and legitimate business purposes. Where the government relies on cooperating witnesses to supply intent, the firm attacks their plea agreements, sentencing exposure, prior inconsistent statements, and incentive to shift responsibility. The firm’s attorneys have cross-examined cooperators in federal healthcare fraud trials for years.
Payment Suspensions, Revocations, and Rebuttal Submissions
For many laboratories, the first sign of trouble is a payment suspension under 42 C.F.R. § 405.371 or a revocation notice under 42 C.F.R. § 424.535. These actions carry short deadlines, and the rebuttal statement or corrective action plan becomes a sworn account that criminal investigators will read. The firm handles the administrative response and the criminal exposure as one problem, because they are one problem.
Seizure, Restraint, and Forfeiture
DOJ now seizes early. The 2026 Takedown included more than $182 million in seized assets and a coordinated effort to seize fraud proceeds from laboratory and clinic accounts before indictment. Frozen operating accounts can end a business and impair the ability to retain counsel. The firm litigates seizure warrants and restraining orders, pursues return of property under Rule 41(g), and contests the government’s tracing analysis where seized funds are not proceeds of any offense.
Federal genetic testing investigations target every link in the chain: the laboratory that bills, the physician or nurse practitioner who signs, the telemedicine platform that supplies orders, the marketer who is paid per sample, and the call center that generates the lead. The 2026 cases show the government charging all of them in the same matters.
Defense of Laboratory Owners and Operators
Laboratory owners remain the primary targets. The government holds them responsible for billing practices, referral sources, and marketer compensation, and charges them with directing claims for medically unnecessary tests, paying per-sample or percentage-based kickbacks, relying on telemarketing-generated orders, or concealing ownership to evade enrollment scrutiny. Loss figures in these cases routinely reach the hundreds of millions of dollars, which drives severe guidelines calculations. The firm defends owners by attacking the government’s proof of personal knowledge, direction, and willfulness, and by testing the loss figure itself.
Defense of Physicians and Nurse Practitioners
Ordering clinicians are charged when the government alleges they signed orders for patients they never treated, completed sham telemedicine encounters, or accepted payment for signatures. Physicians and nurse practitioners were among the defendants sentenced in the $522 million laboratory case resolved in May 2026, and 90 licensed professionals were charged in the June 2026 Takedown. The firm defends clinicians by establishing the clinical basis for orders, documenting the treatment relationship, and separating legitimate medical judgment from the conduct of the marketers who solicited the patient.
Defense of Call Center Owners and Telemarketing Operators
Call center operators are now charged directly, not treated as peripheral. The 2026 Takedown included charges against a call center owner alleged to have sold signed genetic testing orders to laboratories and to have pressured treating physicians by fax to approve tests for patients already “qualified” by non-clinical staff. The firm defends these clients by examining the scripts, the actual representations made, the contractual structure with laboratories, and the evidence of what the operator knew about how orders were used downstream.
Defense of Marketers and Sales Representatives
Marketers face serious exposure because the government treats per-sample and percentage-based compensation as direct evidence of a kickback under the Anti-Kickback Statute and EKRA. Sham marketing invoices and consulting agreements are a recurring feature of the 2026 indictments. The firm defends marketers by analyzing the compensation structure against recognized safe harbors, documenting the services actually performed, and contesting the inference that payment structure alone establishes corrupt intent.
Defense of Telemedicine Executives and Platform Operators
Telemedicine companies and software platforms that supplied signed orders remain high-priority targets. DOJ secured a jury conviction in 2026 against the founder of a platform that connected telemarketing leads to physicians who signed orders in exchange for payment. The firm defends executives by challenging proof of personal involvement, examining the platform’s compliance controls and physician credentialing, and contesting the government’s attribution of downstream conduct to corporate leadership.
Defense of Patient Recruiters and Field Collectors
Individuals who collected DNA samples through telemarketing, door-to-door solicitation, health fairs, or community events are charged when the government alleges they induced beneficiaries to submit to unnecessary testing or to surrender Medicare numbers. All four of those collection methods appear in the May 2026 sentencing record. The firm defends recruiters by contesting evidence of fraudulent intent and by examining what they were told about the testing program they were selling.
These investigations follow a recognizable sequence. Scott Armstrong and Drew Bradylyons built cases this way as senior prosecutors at DOJ. Knowing the sequence tells you what the government already has and what it still needs.
Analytics and Outlier Identification
The case starts with claims data. HHS-OIG, CMS, and the FBI apply machine learning models to Medicare fee-for-service claims to flag laboratories whose volume, test mix, or per-claim values deviate from norms. The Data Fusion Center, staffed by the Healthcare Fraud Unit’s Data Analytics Team, HHS-OIG, and the FBI, was used in many of the cases charged in the 2026 Takedown. Its Financial Intelligence Review Team pairs claims analytics with financial analysis, and in one 2026 matter prosecutors opened an investigation within five days of the financial review.
Payment Suspension and Revocation Before Charges
Money now stops before agents knock. CMS suspended 1,079 providers and revoked 1,403 in connection with the 2026 Takedown, and separately revoked 157 laboratories in its 2026 laboratory enforcement initiative. A suspension often precedes the criminal case. The response a laboratory files at that stage, including its explanation of ordering relationships and medical necessity, becomes an early statement that prosecutors will hold against later positions.
Referral Chain and Supply Chain Analysis
Investigators trace every specimen. They identify who generated the lead, who collected the sample, who signed the order, and who billed. The chain in genetic testing cases is long and fragmented: call centers, marketing companies, telemedicine platforms, ordering providers, and laboratories. Prosecutors map the money between each link and compare payments to referral volume. Fragmentation does not insulate participants. It gives the government more cooperators.
Physician Order Scrutiny and “Doctor Chasing”
The government examines the origin of every order. The recurring 2026 theory is “doctor chasing”: non-clinical call center staff pre-qualify a beneficiary by telephone, then the operator pressures the beneficiary’s treating physician to sign an order for testing the physician did not propose. That theory appeared in both the February 2026 trial conviction in Dallas and the June 2026 call center charges in South Florida. Prosecutors then ask whether the ordering provider examined the patient and whether the results were used in treatment.
Medical Necessity Review
The government retains experts to measure the testing against clinical standards and CMS coverage criteria. Medicare covers CGx testing in narrow circumstances and PGx testing only for specific drug-gene interactions. Investigators look for panels billed for beneficiaries with no relevant history, results never transmitted to a treating physician, and identical high-value panels ordered across unrelated patients.
Kickback and Compensation Analysis
Prosecutors trace payments through bank records, contracts, invoices, and payment applications. Per-sample arrangements disguised as hourly marketing fees are a central 2026 theme, along with payments labeled as software licenses, consulting, or loans. Investigators reconstruct whether invoice amounts were calculated from hours worked or reverse-engineered from sample counts. That arithmetic is often the government’s strongest exhibit, and it is where careful defense analysis matters most.
Cooperating Witnesses
Marketers, recruiters, billers, and ordering providers who plead guilty supply the narrative that connects data anomalies to individual intent. In the $522 million laboratory case sentenced in May 2026, eleven co-conspirators pleaded guilty before the principals were sentenced. Cooperators testify with plea agreements and sentencing exposure in hand. Their accounts are testable against contemporaneous documents, and the differences are the defense.
Search Warrants and Electronic Evidence
Agents seek warrants for phones, laptops, and cloud accounts, and serve providers directly under 18 U.S.C. § 2703 of the Stored Communications Act. Text messages between laboratory principals and marketers are frequently the most damaging evidence at trial. In the February 2026 Dallas trial, the government introduced messages between the laboratory owner and a co-conspirator reacting to Medicare payments.
Seizure, Forfeiture, and Pretrial Release
The Department now moves on assets early and litigates detention aggressively in laboratory cases. Two of the highest-profile genetic testing defendants in 2026 fled after release on bond and were added to the FBI’s Most Wanted Fraudsters List. Prosecutors cite that history in opposing release for other laboratory defendants, and flight adds independent charges and sentencing consequences.
Genetic testing prosecutions stack counts. A single laboratory indictment commonly charges conspiracy, substantive healthcare fraud, kickback counts, and money laundering, with forfeiture allegations attached.
Healthcare Fraud (18 U.S.C. § 1347)
Section 1347 makes it a federal crime to knowingly and willfully execute a scheme to defraud a healthcare benefit program. In genetic testing cases it covers billing for medically unnecessary tests, billing for tests ordered without a genuine treatment relationship, and claims generated through kickback-driven referrals. The maximum is 10 years per count, rising to 20 years where the offense results in serious bodily injury.
Conspiracy (18 U.S.C. §§ 1349, 371)
Section 1349 carries the same maximum penalty as the underlying fraud offense and requires no overt act. It is the government’s preferred charge in supply chain cases because it reaches participants who never submitted a claim. Section 371 conspiracy to defraud the United States and to pay or receive kickbacks appears alongside it in most laboratory indictments.
Anti-Kickback Statute (42 U.S.C. § 1320a-7b)
The Anti-Kickback Statute prohibits knowingly and willfully offering, paying, soliciting, or receiving remuneration to induce or reward referrals for items or services payable by a federal healthcare program. Percentage-based and per-sample marketer compensation is the government’s central theory in genetic testing cases. A claim resulting from a violation is also a false claim under the False Claims Act. Violations carry up to 10 years per count.
EKRA (18 U.S.C. § 220)
The Eliminating Kickbacks in Recovery Act reaches referrals to clinical laboratories regardless of whether a federal program pays the claim. Section 220 carries up to 10 years and a $200,000 fine per violation. Its employee compensation exception is narrower than the corresponding Anti-Kickback safe harbor, and courts have divided on how it applies to sales personnel. Laboratories that structured marketing arrangements around AKS safe harbors alone may still face EKRA exposure on commercially insured volume.
Wire Fraud (18 U.S.C. § 1343)
Wire fraud is charged alongside or as an alternative to healthcare fraud and reaches the electronic submission of claims and the transmission of orders and requisitions. The maximum is 20 years per count, or 30 years where a financial institution is affected.
Money Laundering (18 U.S.C. §§ 1956, 1957)
Money laundering counts follow the proceeds. Prosecutors charge transactions intended to conceal or promote the underlying fraud, and Section 1957 counts for monetary transactions over $10,000 in criminally derived property. Purchases of vehicles, real estate, and luxury goods supply the transactions. Section 1956 carries up to 20 years per count.
Forfeiture and Restitution
Criminal forfeiture under 18 U.S.C. § 982 and restitution are part of every resolution. Restitution in the May 2026 laboratory sentencing exceeded $84.5 million for one defendant. Seizure often occurs before indictment, and substitute assets are available to the government where direct proceeds have been dissipated.
False Claims Act (31 U.S.C. §§ 3729–3733)
The False Claims Act imposes treble damages and per-claim penalties on knowingly false claims. Many genetic testing matters begin as sealed qui tam complaints filed by former employees or marketers and run on parallel civil and criminal tracks. Statements made in an audit response or civil investigative demand can be used in the criminal case.
Revocation, Exclusion, and Licensure Consequences
Medicare enrollment can be revoked under 42 C.F.R. § 424.535 without any criminal charge, with a reenrollment bar attached. A conviction for a program-related offense triggers mandatory exclusion from all federal healthcare programs for a minimum of five years. State licensing boards act independently and frequently move first on a public indictment.
What Did the 2026 National Health Care Fraud Takedown Change for Genetic Testing Laboratories?
The 2026 National Health Care Fraud Takedown, announced June 23, 2026, charged 455 defendants across 56 federal districts in schemes involving more than $6.5 billion in alleged false claims. Ninety of the defendants were doctors or other licensed medical professionals.
Three features matter for laboratories. First, charges reached further up and down the chain, including a call center owner charged in a $62 million genetic testing scheme for selling signed orders to laboratories. Second, the enforcement action was paired with administrative measures on a new scale: 1,079 provider payment suspensions and 1,403 billing privilege revocations announced by CMS. Third, DOJ seized more than $182 million in assets during the two-week window, including funds taken from clinic accounts before indictment.
The Takedown also confirmed the analytical infrastructure behind these cases. DOJ credited its Data Fusion Center, which combines the Healthcare Fraud Unit’s data analysts with HHS-OIG and FBI personnel, and announced the first prosecution generated by its Financial Intelligence Review Team. Laboratories with utilization patterns outside their peer group are now identified in weeks rather than years.
Why Does CMS Suspend Medicare Payments to a Laboratory Before Any Charges Are Filed?
CMS may suspend payment under 42 C.F.R. § 405.371 when it possesses a credible allegation of fraud. No indictment is required, and the suspension can be imposed without prior notice when notice would hinder an investigation. The suspension holds claims payments while the matter is reviewed and is frequently the first visible step in a criminal investigation.
The scale of this activity increased sharply in 2026. CMS announced in August 2026 that it had stopped more than $1.6 billion in potentially improper laboratory payments, including more than $500 million halted through 185 suspensions arising from an investigation of 600 laboratories and $732 million in savings from revoking 157 laboratory providers.
The rebuttal process carries consequences beyond cash flow. A rebuttal statement is a written account of ordering relationships, medical necessity, and marketing arrangements, submitted on a short deadline, and it will be read by the agents building any criminal case. Positions taken in that submission are difficult to revisit later. The administrative and criminal exposure are best evaluated together from the outset.
What Is “Doctor Chasing” and Why Does It Appear in 2026 Genetic Testing Indictments?
“Doctor chasing” describes a specific sequence the government has charged repeatedly in 2026. A call center contacts a Medicare beneficiary, non-clinical staff qualify the beneficiary for a genetic test by telephone, and the operator then identifies the beneficiary’s treating physician and presses that physician to sign an order for testing the physician never proposed.
DOJ described that sequence in the February 2026 trial conviction of a Texas laboratory owner in a $328 million cardiovascular genetic testing case, and again in the June 2026 charges against a South Florida call center owner alleged to have sent physicians faxes containing false and misleading representations to induce orders.
The theory carries legal significance on two elements. It supports the government’s argument that the order did not arise from clinical judgment, which goes to medical necessity. It also supports the inference that payments for the resulting sample were payments for a referral rather than for marketing services. The defense turns on what was actually communicated, what the ordering provider independently reviewed, and whether the laboratory knew how the order was generated.
How Does the Government Prove That CGx or PGx Testing Was Medically Unnecessary?
The government retains experts to review patient records and measure the testing against clinical standards and Medicare coverage criteria. Medicare covers CGx testing in narrow circumstances tied to a personal or family history of cancer and use of the results in an active treatment plan. PGx coverage is limited to specific drug-gene interactions where results will guide prescribing.
Prosecutors typically build the proof from patterns rather than individual charts: identical high-value panels billed across unrelated beneficiaries, testing ordered for patients with no relevant history, results never transmitted to a treating physician, and orders signed by providers with no treatment relationship. Statistical comparisons to peer laboratories supply the scale.
The proof is contestable. Coverage guidance varies by Medicare Administrative Contractor jurisdiction, and HHS-OIG has itself flagged geographic inconsistency, including differences between jurisdictions participating in the Molecular Diagnostic Services Program. Independent genetics and oncology experts can establish a legitimate clinical basis for testing that a government expert reviewing records in bulk did not credit. A coverage dispute is not automatically a fraud case.
Are Per-Sample and Percentage-Based Payments to Genetic Testing Marketers Illegal?
Compensation tied to the volume or value of referrals is the government’s central kickback theory in laboratory cases. Under the Anti-Kickback Statute, remuneration offered to induce referrals for services payable by a federal healthcare program is criminal if offered knowingly and willfully. EKRA extends similar exposure to laboratory referrals regardless of payer, with a narrower employee compensation exception than the corresponding safe harbor.
The 2026 cases focus heavily on concealment. Prosecutors point to invoices billed as marketing hours, software licenses, consulting fees, or loans where the amounts were calculated from sample counts. In the February 2026 Dallas trial, the government showed that invoices purporting to charge for marketing hours had been reverse-engineered to match a per-sample arrangement.
Two legal points frame the defense. Failure to fit within a safe harbor does not establish a violation, and the government must still prove knowing and willful conduct beyond a reasonable doubt. Documented effort to structure an arrangement around a safe harbor, including a written agreement, compensation set in advance, and fair market value support, is affirmative evidence against willfulness.
What Sentences Have Federal Courts Imposed in Genetic Testing Fraud Cases in 2026?
Sentences vary widely by role. In May 2026, the operator of four clinical laboratories in a $522 million genetic testing scheme received 151 months and was ordered to pay more than $84.5 million in restitution. A co-owner who paid kickbacks to marketers received three years.
The eleven co-conspirators sentenced in the same matter show the range below the principals. Marketers received terms from 12 to 46 months. Two nurse practitioners received 24 and 21 months. Two physicians received 12 months each, and a third received six months of home detention and three years of probation.
Guidelines exposure in these cases is driven by intended loss, which in laboratory prosecutions is calculated from billed amounts rather than payments received. That distinction is significant: the $522 million scheme produced roughly $84 million in actual payments. Loss calculation, role adjustments, and the treatment of amounts billed but never paid are among the most consequential litigated issues at sentencing.
Can a Physician or Nurse Practitioner Be Charged for Signing Genetic Testing Orders?
Yes. Licensed clinicians are charged regularly. Ninety doctors and other licensed medical professionals were among the 455 defendants charged in the June 2026 Takedown, and three physicians and two nurse practitioners were sentenced in the $522 million laboratory case resolved in May 2026.
The government’s theory against an ordering provider usually rests on the absence of a treatment relationship, the volume and uniformity of signatures, the speed of review, and payment connected to the signing. Prosecutors examine whether the clinician examined or spoke with the patient, whether results were used in a treatment plan, and whether compensation tracked the number of orders signed.
The defense is fact-specific. It addresses the clinical record supporting each order, the information available to the provider at the time of signing, the provider’s reliance on intake materials and prior records, and the separation between the provider’s conduct and the marketing operation that solicited the patient. A provider who was deceived about how patients were recruited occupies a different position than one who was paid per signature, and the documentary record usually shows which is which.
What Does a Grand Jury Subpoena or Search Warrant Indicate About the Stage of a Laboratory Investigation?
A grand jury subpoena means a federal criminal investigation is open and a prosecutor has presented the matter to a grand jury. In laboratory cases, subpoenas typically seek claims and billing records, requisition forms, marketing agreements, commission schedules, bank records, and communications with ordering providers and marketers.
A search warrant indicates a later and more serious stage. It requires a judicial finding of probable cause, which means the government has already assembled evidence sufficient to persuade a magistrate that a crime occurred and that evidence of it exists at the location. Warrants for cloud accounts are served directly on service providers under 18 U.S.C. § 2703, often without the account holder learning of it immediately.
Both events carry preservation obligations, and the response itself creates evidence. Deleted messages, altered records, and inconsistent statements to agents generate independent charges for obstruction and false statements. In one 2026 healthcare fraud trial, fabricated records produced in response to a grand jury subpoena added obstruction counts to the underlying fraud case.
How Do Parallel Civil False Claims Act and Criminal Genetic Testing Investigations Interact?
Many genetic testing matters begin with a sealed qui tam complaint filed under the False Claims Act by a former employee, billing contractor, or marketer. The complaint remains under seal while the government investigates, and the defendant may not learn of it for a year or more. Civil investigative demands, OIG audits, and payment suspensions can all proceed during that period.
The tracks are connected. Civil FCA liability attaches to claims tainted by a kickback, so the same marketing arrangement drives both cases. Statements made in an audit response, a civil investigative demand response, or a deposition can be used by criminal prosecutors. Sequencing decisions, including whether and when to make factual submissions, have consequences across both proceedings.
Civil exposure is substantial on its own. The FCA imposes treble damages plus per-claim penalties, and in laboratory cases the claim count can run into the thousands. Coordinated defense across the criminal, civil, and administrative tracks avoids resolving one at the cost of the others.
What Are the Consequences of Failing to Appear in a Federal Health Care Fraud Case?
Flight creates independent criminal exposure and hardens every other aspect of the case. Failure to appear is a separate felony under 18 U.S.C. § 3146 that does not depend on the outcome of the underlying charges. At sentencing, flight supports an obstruction enhancement and ordinarily forfeits any reduction for acceptance of responsibility.
Genetic testing defendants are now a visible part of this enforcement effort. On June 23, 2026, the FBI added two genetic testing fugitives to its Most Wanted Fraudsters List: a defendant wanted in a $547 million scheme who fled after release on bond over the government’s objection, and a laboratory owner wanted in a $90 million scheme who removed her ankle monitor and left the country by private charter using a false passport.
Countries without an extradition treaty do not provide shelter. Governments routinely return fugitives through visa cancellation and deportation. During the 2026 Takedown, defendants were returned from Cyprus, Estonia, and the Philippines. Fugitive status also triggers the disentitlement doctrine, which can bar a defendant from seeking relief in the courts he is evading.
Does a Genetic Testing Fraud Case End Participation in Medicare and Medicaid?
Program consequences can arrive well before a conviction. CMS may revoke Medicare enrollment under 42 C.F.R. § 424.535 on administrative grounds, including a determination that a provider submitted claims for services that could not have been furnished. Revocation carries a reenrollment bar. CMS revoked 157 laboratory providers in its 2026 laboratory initiative and 1,403 providers in connection with the June 2026 Takedown.
A conviction for a program-related criminal offense triggers mandatory exclusion by HHS-OIG for a minimum of five years, and OIG has permissive exclusion authority in a broader set of circumstances. An excluded individual cannot be employed by, or furnish services reimbursed by, any federal healthcare program.
State licensing boards act on their own timetable and often move on a public indictment rather than waiting for a verdict. Private payer network terminations and CLIA consequences frequently follow. For laboratories and clinicians, these collateral proceedings can be as consequential as the criminal case and require attention while it is pending.
Why Does Federal Trial Experience Matter in a Genetic Testing Fraud Defense?
Because the government is trying these cases and winning them. DOJ’s Healthcare Fraud Unit reported nine completed jury trials in the first half of 2026, all resulting in convictions, following 17 trials in 2025. The Unit pairs trial-designated prosecutors with data analysts and dedicates Assistant Chiefs to trial supervision. A defense premised on negotiating a resolution is negotiating against an office that prefers verdicts.
Trial capability also shapes the pretrial record. Counsel preparing for trial builds the expert record on medical necessity early, litigates the government’s summary exhibits and statistical extrapolations, develops impeachment material on cooperating witnesses before they are locked into testimony, and preserves the issues that matter on appeal.
Armstrong & Bradylyons PLLC brings 25 federal jury trials in complex fraud cases, including 17 healthcare fraud trials at DOJ involving more than $2.8 billion in alleged false claims. The firm defends laboratory owners, clinicians, marketers, and executives in federal healthcare fraud matters in every federal district where genetic testing cases are investigated and charged.